CN1988898B - 用于治疗视觉障碍的视黄醛衍生物及其使用方法 - Google Patents

用于治疗视觉障碍的视黄醛衍生物及其使用方法 Download PDF

Info

Publication number
CN1988898B
CN1988898B CN2005800240983A CN200580024098A CN1988898B CN 1988898 B CN1988898 B CN 1988898B CN 2005800240983 A CN2005800240983 A CN 2005800240983A CN 200580024098 A CN200580024098 A CN 200580024098A CN 1988898 B CN1988898 B CN 1988898B
Authority
CN
China
Prior art keywords
cis
retinyl
ester
retinal
retinyl ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800240983A
Other languages
English (en)
Chinese (zh)
Other versions
CN1988898A (zh
Inventor
克日什托夫·帕尔切夫斯凯
马修·巴滕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WASHINGTON, University of
Original Assignee
WASHINGTON, University of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WASHINGTON, University of filed Critical WASHINGTON, University of
Priority to CN201210458886.5A priority Critical patent/CN102976937B/zh
Publication of CN1988898A publication Critical patent/CN1988898A/zh
Application granted granted Critical
Publication of CN1988898B publication Critical patent/CN1988898B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/10—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/12—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2005800240983A 2004-06-18 2005-06-20 用于治疗视觉障碍的视黄醛衍生物及其使用方法 Expired - Fee Related CN1988898B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210458886.5A CN102976937B (zh) 2004-06-18 2005-06-20 用于治疗视觉障碍的视黄醛衍生物及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58088904P 2004-06-18 2004-06-18
US60/580,889 2004-06-18
PCT/US2005/021812 WO2006002097A2 (en) 2004-06-18 2005-06-20 Retinal derivatives and methods for the use thereof for the treatment of visual disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201210458886.5A Division CN102976937B (zh) 2004-06-18 2005-06-20 用于治疗视觉障碍的视黄醛衍生物及其使用方法

Publications (2)

Publication Number Publication Date
CN1988898A CN1988898A (zh) 2007-06-27
CN1988898B true CN1988898B (zh) 2012-12-26

Family

ID=35782277

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2005800240983A Expired - Fee Related CN1988898B (zh) 2004-06-18 2005-06-20 用于治疗视觉障碍的视黄醛衍生物及其使用方法
CN201210458886.5A Expired - Fee Related CN102976937B (zh) 2004-06-18 2005-06-20 用于治疗视觉障碍的视黄醛衍生物及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201210458886.5A Expired - Fee Related CN102976937B (zh) 2004-06-18 2005-06-20 用于治疗视觉障碍的视黄醛衍生物及其使用方法

Country Status (26)

Country Link
US (8) US7951841B2 (enExample)
EP (5) EP2397131B1 (enExample)
JP (2) JP5166026B2 (enExample)
KR (4) KR101337321B1 (enExample)
CN (2) CN1988898B (enExample)
AU (1) AU2005257997B2 (enExample)
BR (1) BRPI0511396B1 (enExample)
CA (2) CA2571049C (enExample)
CY (2) CY1114873T1 (enExample)
DK (2) DK2397133T3 (enExample)
ES (4) ES2644984T3 (enExample)
HR (1) HRP20140116T1 (enExample)
HU (1) HUE036596T2 (enExample)
IL (4) IL180078A (enExample)
IN (1) IN2012DN09335A (enExample)
LT (1) LT2397133T (enExample)
MX (2) MX359668B (enExample)
NO (1) NO339969B1 (enExample)
NZ (2) NZ587006A (enExample)
PL (2) PL1765322T3 (enExample)
PT (2) PT1765322E (enExample)
RS (1) RS53178B (enExample)
RU (2) RU2408578C2 (enExample)
SI (2) SI1765322T1 (enExample)
WO (1) WO2006002097A2 (enExample)
ZA (1) ZA200700368B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281821A1 (en) 2003-03-14 2006-12-14 Krzysztof Palczewski Retinoid replacements and opsin agonists and methods for the use thereof
AU2005257997B2 (en) 2004-06-18 2012-04-05 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
KR100862930B1 (ko) 2004-06-23 2008-10-13 시리온 테라퓨틱스, 인크. 레티닐 유도체를 사용하여 안 증상을 치료하기 위한 방법및 조성물
EP1930046A1 (en) * 2004-12-08 2008-06-11 Sirion Therapeutics, Inc. Retinol binding protein and transthyretin modulators for treating diabetes
AU2007277032A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Opsin stabilizing compounds and methods of use
EP2069391A4 (en) * 2006-07-27 2009-12-30 Univ Florida COMPOSITIONS AND METHODS FOR TREATING AND / OR PREVENTING OPHTHALMOLOGICAL DISEASES
WO2008063768A2 (en) * 2006-10-12 2008-05-29 Case Western Reserve University Compositions and methods for treating metabolic diseases
MX2009011360A (es) 2007-04-20 2010-02-12 Acucela Inc Compuestos derivados de estirenilo para tratar enfermedades y trastornos oftalmicos.
US8324270B2 (en) * 2008-02-11 2012-12-04 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
AU2015200520B2 (en) * 2008-02-11 2017-02-09 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
JP5443470B2 (ja) * 2008-04-29 2014-03-19 株式会社日健総本社 眼障害の治療方法
IN2012DN00352A (enExample) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
RU2546005C2 (ru) * 2009-09-15 2015-04-10 Кью Эл Ти ИНК. Фармацевтические составы, содержащие 9-цис-ретиниловые сложные эфиры в липидном наполнителе
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
US8889660B2 (en) 2010-01-20 2014-11-18 Case Western Reserve University Methods for treating obesity or an obesity related condition
SG10201507819VA (en) * 2010-04-19 2015-10-29 Quadra Logic Tech Inc Therapeutic Regimen And Methods For Treating Or Ameliorating Visual Disorders Associated With An Endogenous Retinoid Deficiency
CN103384469B (zh) * 2010-11-05 2016-06-15 斯坦福大学托管董事会 光控cns功能障碍
WO2013082149A1 (en) * 2011-11-28 2013-06-06 Case Western Reserve University Polysaccharide therapeutic conjugates
AU2013232697B2 (en) * 2012-03-01 2017-10-19 Eluminex Biosciences (Suzhou) Limited Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
US20150038582A1 (en) * 2012-03-01 2015-02-05 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
EP2858648B1 (en) 2012-06-07 2018-08-22 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
US20150119388A1 (en) * 2012-06-15 2015-04-30 The Children's Hospital Philadelphia Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges
US10471118B2 (en) 2014-05-30 2019-11-12 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US12060318B2 (en) 2015-10-09 2024-08-13 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
CA3022386A1 (en) * 2016-04-28 2017-11-02 Spark Therapeutics, Inc. Relative potency assay for viral vector encoding isomerohydrolases
EP4161502A4 (en) * 2020-06-09 2024-07-10 Eluminex Biosciences (Suzhou) Limited Methods of treating visual disorders using daily low dosing of a retinoid compound
EP4472736A4 (en) * 2022-02-04 2026-01-21 Univ New York USE OF RETINOIDS FOR THE TREATMENT OF ATRIAL FIBRILLATION

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1185729A (zh) * 1995-04-03 1998-06-24 庄臣消费品有限公司 含有类视色素和脂质体的护肤组合物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797977A (en) * 1956-01-16 1958-07-09 Hoffmann La Roche Vitamin-a esters and a process for the manufacture thereof
US3196048A (en) 1961-12-19 1965-07-20 Exxon Research Engineering Co Cathode catalyst for fuel cells
US3196078A (en) * 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) * 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) * 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
DE2456959A1 (de) * 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
US5310764A (en) * 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
EP0754046A1 (en) 1994-04-04 1997-01-22 FREEMAN, William R. Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
RU2106843C1 (ru) * 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) * 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) * 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US5620970A (en) * 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
US5716627A (en) * 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (en) * 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
US6391924B1 (en) 1997-12-10 2002-05-21 Hampar Karageozian Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en) * 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
US6300328B1 (en) * 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
CA2373237A1 (en) 2000-03-10 2001-09-20 Insite Vision Incorporated Methods and compositions for treating and preventing posterior segment ophthalmic disorders
US20020028849A1 (en) * 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) * 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
EP1261623B1 (en) * 2001-01-11 2009-11-04 Chebigen Inc. New retinol derivatives, the method of preparations and the uses thereof
AU2002240141A1 (en) 2001-01-26 2002-08-06 Steven Baranowitz Systemic formulations containing beta-carotene and derivatives thereof
GB0103998D0 (en) 2001-02-19 2001-04-04 King S College London Method
CA2442670A1 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
CA2474154A1 (en) * 2002-01-18 2003-07-24 Tatton Technologies, Llc. Methods for treating eye disorders
US20030215413A1 (en) * 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) * 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
CN1741811A (zh) 2002-03-29 2006-03-01 马克西姆医药公司 Rom产生与释放抑制剂治疗和预防眼内损伤的用途
US20060281821A1 (en) 2003-03-14 2006-12-14 Krzysztof Palczewski Retinoid replacements and opsin agonists and methods for the use thereof
WO2005079774A2 (en) 2004-02-17 2005-09-01 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
US7566808B2 (en) * 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
CN1964706A (zh) 2004-03-17 2007-05-16 拉斯·M·拉森 通过抑制视觉周期预防视网膜病
AU2005257997B2 (en) 2004-06-18 2012-04-05 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
KR100862930B1 (ko) 2004-06-23 2008-10-13 시리온 테라퓨틱스, 인크. 레티닐 유도체를 사용하여 안 증상을 치료하기 위한 방법및 조성물
AU2005287343A1 (en) 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
WO2006039551A2 (en) 2004-09-30 2006-04-13 The Regents Of The University Of California Local administration of retinoids to treat deficiencies in dark adaptation
JP5149388B2 (ja) 2007-09-12 2013-02-20 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 黄斑変性症を処置するための組成物及び方法
US8324270B2 (en) 2008-02-11 2012-12-04 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1185729A (zh) * 1995-04-03 1998-06-24 庄臣消费品有限公司 含有类视色素和脂质体的护肤组合物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Driessen et al.Disruption of the 11-cis-Retinol Dehydrogenase Gene Leadsto Accumulation of cis-Retinols and cis-Retinyl Esters.Molecular and Cellular Biology20 12.2000,20(12),摘要.
Driessen et al.Disruption of the 11-cis-Retinol Dehydrogenase Gene Leadsto Accumulation of cis-Retinols and cis-Retinyl Esters.Molecular and Cellular Biology20 12.2000,20(12),摘要. *
JP特开平6-340525A 1994.12.13
JP特开平8-198746A 1996.08.06
沈丹蓓.由全反式维A酸和全反式视黄基-b-D葡糖苷酸传导的维A酸信号可因人角质形成细胞暴露于视黄醇中而减弱.国外医学，皮肤性病学分册 6.1999,(6),380-381.
沈丹蓓.由全反式维A酸和全反式视黄基-b-D葡糖苷酸传导的维A酸信号可因人角质形成细胞暴露于视黄醇中而减弱.国外医学,皮肤性病学分册 6.1999,(6),380-381. *

Also Published As

Publication number Publication date
HK1098696A1 (en) 2007-07-27
PL1765322T3 (pl) 2014-04-30
US7951841B2 (en) 2011-05-31
ES2443194T3 (es) 2014-02-18
EP2397132A3 (en) 2012-07-11
AU2005257997A1 (en) 2006-01-05
JP5166026B2 (ja) 2013-03-21
IL180078A (en) 2014-01-30
BRPI0511396A (pt) 2007-12-04
RU2408578C2 (ru) 2011-01-10
EP2397132A2 (en) 2011-12-21
US9162978B2 (en) 2015-10-20
US9403765B2 (en) 2016-08-02
SI1765322T1 (sl) 2014-03-31
MXPA06014750A (es) 2007-03-21
JP2012229234A (ja) 2012-11-22
US20170014368A1 (en) 2017-01-19
US20190167626A1 (en) 2019-06-06
EP2397130A2 (en) 2011-12-21
CY1119480T1 (el) 2018-03-07
EP1765322B1 (en) 2013-11-06
US20130072560A1 (en) 2013-03-21
RU2007101735A (ru) 2008-07-27
DK1765322T3 (da) 2014-02-10
DK2397133T3 (en) 2017-10-30
EP2397132B1 (en) 2017-07-26
KR101490145B1 (ko) 2015-02-05
HRP20140116T1 (hr) 2014-03-28
ES2752924T3 (es) 2020-04-06
NO20070330L (no) 2007-03-15
RS53178B (sr) 2014-06-30
KR20070026817A (ko) 2007-03-08
CA2571049C (en) 2016-08-09
AU2005257997B2 (en) 2012-04-05
IL180078A0 (en) 2007-05-15
PT2397133T (pt) 2017-10-23
US20130079403A1 (en) 2013-03-28
KR20140140616A (ko) 2014-12-09
WO2006002097A3 (en) 2006-05-04
KR101337321B1 (ko) 2013-12-06
KR20120062946A (ko) 2012-06-14
CN102976937A (zh) 2013-03-20
KR101323122B1 (ko) 2013-10-30
EP2397130A3 (en) 2012-10-31
ZA200700368B (en) 2008-10-29
LT2397133T (lt) 2018-01-10
PL2397133T3 (pl) 2018-01-31
NO339969B1 (no) 2017-02-20
US10117845B2 (en) 2018-11-06
BRPI0511396B1 (pt) 2021-07-27
NZ587006A (en) 2011-12-22
CN102976937B (zh) 2016-12-21
KR20130079669A (ko) 2013-07-10
HUE036596T2 (hu) 2018-07-30
EP2397133A2 (en) 2011-12-21
WO2006002097A2 (en) 2006-01-05
IL230241A (en) 2015-06-30
ES2644981T3 (es) 2017-12-01
EP2397133A3 (en) 2012-07-11
US20110288170A1 (en) 2011-11-24
ES2644984T3 (es) 2017-12-01
EP2397130B1 (en) 2019-04-03
EP2397133B1 (en) 2017-07-26
JP2008503496A (ja) 2008-02-07
SI2397133T1 (sl) 2017-12-29
US9388130B2 (en) 2016-07-12
US20080221208A1 (en) 2008-09-11
CN1988898A (zh) 2007-06-27
PT1765322E (pt) 2014-02-05
IL222347A (en) 2017-08-31
EP2397131B1 (en) 2019-09-11
RU2554003C2 (ru) 2015-06-20
US20130072559A1 (en) 2013-03-21
NZ552080A (en) 2011-03-31
IN2012DN09335A (enExample) 2015-08-21
RU2010138410A (ru) 2012-03-27
IL230242A (en) 2015-10-29
EP1765322A4 (en) 2008-09-17
CY1114873T1 (el) 2016-12-14
EP2397131A2 (en) 2011-12-21
MX359668B (es) 2018-10-05
EP1765322A2 (en) 2007-03-28
US9174936B2 (en) 2015-11-03
JP5596749B2 (ja) 2014-09-24
CA2571049A1 (en) 2006-01-05
CA2931917A1 (en) 2006-01-05
US20130072556A1 (en) 2013-03-21
US9169204B2 (en) 2015-10-27
EP2397131A3 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
US20190167626A1 (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
AU2015207903B2 (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
HK1183659A (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
HK1183659B (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
HK1165696A (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
HK1165298A (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
HK1165299A (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
HK1165300A (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
HK1165300B (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
HK1098696B (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
HK1165299B (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121226

CF01 Termination of patent right due to non-payment of annual fee